Amgen's multibillion-dollar collaboration with Novartis AG to jointly develop and market Amgen’s popular migraine-prevention treatment, Aimovig, triggered legal headaches for both companies in the U.S. The drugmakers on April 4 filed separate lawsuits in Manhattan federal court, accusing each other of violating two collaboration agreements they struck in 2015 and 2017 to work together and…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
